Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation

Renato Cunha, Marco A. Zago, Sergio Querol, Fernanda Volt, Annalisa Ruggeri, Guillermo Sanz, Fabienne Pouthier, Gesine Kogler, José L. Vicario, Paola Bergamaschi, Riccardo Saccardi, Carmen H. Lamas, Cristina Díaz-De-Heredia, Gerard Michel, Henrique Bittencourt, Marli Tavella, Rodrigo A. Panepucci, Francisco Fernandes, Julia Pavan, Eliane Gluckman & 2 others Vanderson Rocha, Cord Blood Committee Cellular Therapy-Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We evaluated the impact of recipient and cord blood unit (CBU) genetic polymorphisms related to immune response on outcomes after unrelated cord blood transplantations (CBTs). Pretransplant DNA samples from 696 CBUs with malignant diseases were genotyped for NLRP1, NLRP2, NLRP3, TIRAP/Mal, IL10, REL, TNFRSF1B, and CTLA4. HLA compatibility was 6 of 6 in 10%, 5 of 6 in 39%, and ≥4 of 6 in 51% of transplants. Myeloablative conditioning was used in 80%, and in vivo T-cell depletion in 81%, of cases. The median number of total nucleated cells infused was 3.4 × 107/kg. In multivariable analysis, patients receiving CBUs with GG-CTLA4 genotype had poorer neutrophil recovery (hazard ratio [HR], 1.33; P = .02), increased nonrelapse mortality (NRM) (HR, 1.50; P < .01), and inferior disease-free survival (HR, 1.41; P = .02). We performed the same analysis in a more homogeneous subset of cohort 1 (cohort 2, n = 305) of patients who received transplants for acute leukemia, all given a myeloablative conditioning regimen, and with available allele HLA typing (HLA-A, -B, -C, and -DRB1). In this more homogeneous but smaller cohort, we were able to demonstrate that GG-CTLA4-CBU was associated with increased NRM (HR, 1.85; P = .01). Use of GG-CTLA4-CBU was associated with higher mortality after CBT, which may be a useful criterion for CBU selection, when multiple CBUs are available.

Original languageEnglish
Pages (from-to)525-532
Number of pages8
JournalBlood
Volume129
Issue number4
DOIs
Publication statusPublished - Jan 26 2017

Fingerprint

Polymorphism
Fetal Blood
Blood
Genes
Transplantation
Genotype
Hazards
Transplants
Mortality
Histocompatibility Testing
HLA-A Antigens
HLA-B Antigens
T-cells
Genetic Polymorphisms
Interleukin-10
Disease-Free Survival
Leukemia
Neutrophils
Alleles
T-Lymphocytes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Cunha, R., Zago, M. A., Querol, S., Volt, F., Ruggeri, A., Sanz, G., ... Cord Blood Committee Cellular Therapy-Immunobiology Working Party of the European Society for Blood and Marrow Transplantation (2017). Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation. Blood, 129(4), 525-532. https://doi.org/10.1182/blood-2016-06-722249

Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation. / Cunha, Renato; Zago, Marco A.; Querol, Sergio; Volt, Fernanda; Ruggeri, Annalisa; Sanz, Guillermo; Pouthier, Fabienne; Kogler, Gesine; Vicario, José L.; Bergamaschi, Paola; Saccardi, Riccardo; Lamas, Carmen H.; Díaz-De-Heredia, Cristina; Michel, Gerard; Bittencourt, Henrique; Tavella, Marli; Panepucci, Rodrigo A.; Fernandes, Francisco; Pavan, Julia; Gluckman, Eliane; Rocha, Vanderson; Cord Blood Committee Cellular Therapy-Immunobiology Working Party of the European Society for Blood and Marrow Transplantation.

In: Blood, Vol. 129, No. 4, 26.01.2017, p. 525-532.

Research output: Contribution to journalArticle

Cunha, R, Zago, MA, Querol, S, Volt, F, Ruggeri, A, Sanz, G, Pouthier, F, Kogler, G, Vicario, JL, Bergamaschi, P, Saccardi, R, Lamas, CH, Díaz-De-Heredia, C, Michel, G, Bittencourt, H, Tavella, M, Panepucci, RA, Fernandes, F, Pavan, J, Gluckman, E, Rocha, V & Cord Blood Committee Cellular Therapy-Immunobiology Working Party of the European Society for Blood and Marrow Transplantation 2017, 'Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation', Blood, vol. 129, no. 4, pp. 525-532. https://doi.org/10.1182/blood-2016-06-722249
Cunha, Renato ; Zago, Marco A. ; Querol, Sergio ; Volt, Fernanda ; Ruggeri, Annalisa ; Sanz, Guillermo ; Pouthier, Fabienne ; Kogler, Gesine ; Vicario, José L. ; Bergamaschi, Paola ; Saccardi, Riccardo ; Lamas, Carmen H. ; Díaz-De-Heredia, Cristina ; Michel, Gerard ; Bittencourt, Henrique ; Tavella, Marli ; Panepucci, Rodrigo A. ; Fernandes, Francisco ; Pavan, Julia ; Gluckman, Eliane ; Rocha, Vanderson ; Cord Blood Committee Cellular Therapy-Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. / Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation. In: Blood. 2017 ; Vol. 129, No. 4. pp. 525-532.
@article{8e1ba43363ee413c8a0f4b233c5a207d,
title = "Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation",
abstract = "We evaluated the impact of recipient and cord blood unit (CBU) genetic polymorphisms related to immune response on outcomes after unrelated cord blood transplantations (CBTs). Pretransplant DNA samples from 696 CBUs with malignant diseases were genotyped for NLRP1, NLRP2, NLRP3, TIRAP/Mal, IL10, REL, TNFRSF1B, and CTLA4. HLA compatibility was 6 of 6 in 10{\%}, 5 of 6 in 39{\%}, and ≥4 of 6 in 51{\%} of transplants. Myeloablative conditioning was used in 80{\%}, and in vivo T-cell depletion in 81{\%}, of cases. The median number of total nucleated cells infused was 3.4 × 107/kg. In multivariable analysis, patients receiving CBUs with GG-CTLA4 genotype had poorer neutrophil recovery (hazard ratio [HR], 1.33; P = .02), increased nonrelapse mortality (NRM) (HR, 1.50; P < .01), and inferior disease-free survival (HR, 1.41; P = .02). We performed the same analysis in a more homogeneous subset of cohort 1 (cohort 2, n = 305) of patients who received transplants for acute leukemia, all given a myeloablative conditioning regimen, and with available allele HLA typing (HLA-A, -B, -C, and -DRB1). In this more homogeneous but smaller cohort, we were able to demonstrate that GG-CTLA4-CBU was associated with increased NRM (HR, 1.85; P = .01). Use of GG-CTLA4-CBU was associated with higher mortality after CBT, which may be a useful criterion for CBU selection, when multiple CBUs are available.",
author = "Renato Cunha and Zago, {Marco A.} and Sergio Querol and Fernanda Volt and Annalisa Ruggeri and Guillermo Sanz and Fabienne Pouthier and Gesine Kogler and Vicario, {Jos{\'e} L.} and Paola Bergamaschi and Riccardo Saccardi and Lamas, {Carmen H.} and Cristina D{\'i}az-De-Heredia and Gerard Michel and Henrique Bittencourt and Marli Tavella and Panepucci, {Rodrigo A.} and Francisco Fernandes and Julia Pavan and Eliane Gluckman and Vanderson Rocha and {Cord Blood Committee Cellular Therapy-Immunobiology Working Party of the European Society for Blood and Marrow Transplantation}",
year = "2017",
month = "1",
day = "26",
doi = "10.1182/blood-2016-06-722249",
language = "English",
volume = "129",
pages = "525--532",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation

AU - Cunha, Renato

AU - Zago, Marco A.

AU - Querol, Sergio

AU - Volt, Fernanda

AU - Ruggeri, Annalisa

AU - Sanz, Guillermo

AU - Pouthier, Fabienne

AU - Kogler, Gesine

AU - Vicario, José L.

AU - Bergamaschi, Paola

AU - Saccardi, Riccardo

AU - Lamas, Carmen H.

AU - Díaz-De-Heredia, Cristina

AU - Michel, Gerard

AU - Bittencourt, Henrique

AU - Tavella, Marli

AU - Panepucci, Rodrigo A.

AU - Fernandes, Francisco

AU - Pavan, Julia

AU - Gluckman, Eliane

AU - Rocha, Vanderson

AU - Cord Blood Committee Cellular Therapy-Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

PY - 2017/1/26

Y1 - 2017/1/26

N2 - We evaluated the impact of recipient and cord blood unit (CBU) genetic polymorphisms related to immune response on outcomes after unrelated cord blood transplantations (CBTs). Pretransplant DNA samples from 696 CBUs with malignant diseases were genotyped for NLRP1, NLRP2, NLRP3, TIRAP/Mal, IL10, REL, TNFRSF1B, and CTLA4. HLA compatibility was 6 of 6 in 10%, 5 of 6 in 39%, and ≥4 of 6 in 51% of transplants. Myeloablative conditioning was used in 80%, and in vivo T-cell depletion in 81%, of cases. The median number of total nucleated cells infused was 3.4 × 107/kg. In multivariable analysis, patients receiving CBUs with GG-CTLA4 genotype had poorer neutrophil recovery (hazard ratio [HR], 1.33; P = .02), increased nonrelapse mortality (NRM) (HR, 1.50; P < .01), and inferior disease-free survival (HR, 1.41; P = .02). We performed the same analysis in a more homogeneous subset of cohort 1 (cohort 2, n = 305) of patients who received transplants for acute leukemia, all given a myeloablative conditioning regimen, and with available allele HLA typing (HLA-A, -B, -C, and -DRB1). In this more homogeneous but smaller cohort, we were able to demonstrate that GG-CTLA4-CBU was associated with increased NRM (HR, 1.85; P = .01). Use of GG-CTLA4-CBU was associated with higher mortality after CBT, which may be a useful criterion for CBU selection, when multiple CBUs are available.

AB - We evaluated the impact of recipient and cord blood unit (CBU) genetic polymorphisms related to immune response on outcomes after unrelated cord blood transplantations (CBTs). Pretransplant DNA samples from 696 CBUs with malignant diseases were genotyped for NLRP1, NLRP2, NLRP3, TIRAP/Mal, IL10, REL, TNFRSF1B, and CTLA4. HLA compatibility was 6 of 6 in 10%, 5 of 6 in 39%, and ≥4 of 6 in 51% of transplants. Myeloablative conditioning was used in 80%, and in vivo T-cell depletion in 81%, of cases. The median number of total nucleated cells infused was 3.4 × 107/kg. In multivariable analysis, patients receiving CBUs with GG-CTLA4 genotype had poorer neutrophil recovery (hazard ratio [HR], 1.33; P = .02), increased nonrelapse mortality (NRM) (HR, 1.50; P < .01), and inferior disease-free survival (HR, 1.41; P = .02). We performed the same analysis in a more homogeneous subset of cohort 1 (cohort 2, n = 305) of patients who received transplants for acute leukemia, all given a myeloablative conditioning regimen, and with available allele HLA typing (HLA-A, -B, -C, and -DRB1). In this more homogeneous but smaller cohort, we were able to demonstrate that GG-CTLA4-CBU was associated with increased NRM (HR, 1.85; P = .01). Use of GG-CTLA4-CBU was associated with higher mortality after CBT, which may be a useful criterion for CBU selection, when multiple CBUs are available.

UR - http://www.scopus.com/inward/record.url?scp=85014894859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014894859&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-06-722249

DO - 10.1182/blood-2016-06-722249

M3 - Article

VL - 129

SP - 525

EP - 532

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -